The Usage of Acetylsalicylic Acid for Lenalidomide Medication in Patients with Multiple Myeloma

DOI Web Site
  • Kikuchi Daisuke
    Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital Division of Molecular Epidemiology, Tohoku University Graduate School of Medicine
  • Obara Taku
    Division of Molecular Epidemiology, Tohoku University Graduate School of Medicine Department of Pharmaceutical Sciences, Tohoku University Hospital
  • Miura Ryosuke
    Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital
  • Takahashi Shota
    Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital
  • Kashiwagura Shota
    Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital
  • Okada Kouji
    Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital Department of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University
  • Watanabe Yoshiteru
    Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital Department of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University

Bibliographic Information

Other Title
  • Lenalidomide 使用中の多発性骨髄腫患者における acetylsalicylic acid の使用状況
  • Lenalidomide使用中の多発性骨髄腫患者におけるacetylsalicylic acidの使用状況 : MDV analyzerを用いた診療データに基づく実態調査
  • Lenalidomide シヨウ チュウ ノ タハツセイ コツズイシュ カンジャ ニ オケル acetylsalicylic acid ノ シヨウ ジョウキョウ : MDV analyzer オ モチイタ シンリョウ データ ニ モトズク ジッタイ チョウサ
  • ―Survey on Actual Condition of Clinical Data Using MDVAnalyzer―
  • ―MDV analyzer を用いた診療データに基づく実態調査―

Search this article

Description

<p>Lenalidomide (LD) was reported to increase the risk of thromboembolism when it was used along with dexamethasone (DEX). Prophylactic administration of antithrombotic drugs against thromboembolism has been recommended for proper use of LD, but none of the recommendation is stated in the package insert. The purpose of this study was to elucidate the usage of acetylsalicylic acid (ASA) for lenalidomide medication in patients withmultiple myeloma. We used the MDV analyzer to investigate clinical data retrospectively. The investigation period was from October 1, 2016 to September 30, 2017. Subjects were outpatients aged 20 years or older who were recorded in clinical data as multiple myeloma. There were 7,590 outpatients with multiple myeloma. They were divided into 4 groups by the combined use situation of LD and DEX: LD/DEX non-use group (n＝5,462), DEX alone group (n＝632),LD alone group (n＝203), and LD/DEX together group (n＝1,293), respectively. The prevalence rate of thromboembolism was 7.3% in the DEX alone group and 16.9% in the LD/DEX together group (p＜0.0001). Among the LD/DEX together group, ASA was prescribed at 63.6% in the group without thromboembolism (n＝1,074). The prevalence rate of thromboembolism was higher in the LD/DEX combined group than in the DEX alone group. Considering these findings, risk management for thromboembolism caused by administration of antithrombotic drugs should be considered. It is necessary to create more evidence concerning the necessity of administration of antithrombotic drug in combination with LD/DEX medication.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top